operating margin
—
FY 2027
management target
INDOCO REMEDIES LIMITED
Last · NSE₹247.00+20.45 (+9.03%)close · yahoo · 6h ago
Market cap₹22.8B92.2M sh
P/E · TTM748fwd 20.3 · eps 0.33
Beta0.62vs S&P 500
Div yield0.09%annual · TTM
52w range
₹162.19₹301.95
Volume162.8Ksession
Loading chart…
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strong BuyBuyHoldSellStrong Sell
Wait for regulatory clearance, sustained cash generation and debt reduction before buying.
Hold: Q1 consolidated revenue rose 8.2% to INR4,662 million and EBITDA margin improved to 8.8%, but the quarter still leaves a leveraged, execution-dependent story.
The bull case is 62.2% U.S. revenue growth, 42.4% API growth and operating efficiencies; the bear case is INR930 crore of debt, a still-pending U.S. FDA audit that blocks sterile launches, and only an aspirational path to double-digit margins.
Themes
- Regulatory Clearance
- Us Pharma
- Debt Reduction
- Margin Recovery
- Api Growth
- Domestic Brands
Near term
U.S. FDA audit timing is the key near-term catalyst; sterile product approvals and launches remain held up after more than six months of waiting.
European revenue was up only 2.5% and emerging-market revenue fell 31.2% year on year; management attributes this to order timing and prior-quarter primary billing, but the rebound must be demonstrated.
Starting-material inflation lifted COGS by about 200 basis points and management expects part of the pressure to persist into Q2 and Q3.
Management targets INR110 crore of debt repayment this year while working-capital needs remain material.
Longer term
Domestic and emerging businesses are described as capable of roughly 10% to 11% CAGR over the next two to three years, with midsized brands intended to become larger brands.
API growth and manufacturing-efficiency work could improve margins, but the U.S. sterile facility has high fixed operating costs until it can run at meaningful utilization.
The oral-care business is still loss-making at the margin and requires at least three years of advertising and consumer-awareness investment.
Red flags
The U.S. business is not yet profitable in its sterile component and management declined to provide U.S. guidance pending regulatory clarity.
Debt remains high at about INR930 crore, including roughly INR600 crore long-term and INR325 crore short-term debt, while the company is still working toward profitability above interest and depreciation.
Management repeatedly relies on timing explanations for weak Europe and emerging-market results and did not quantify a firm timeline for the FDA audit.
The planned land sale and ophthalmic-division proceeds are only partly available for debt repayment because working capital also requires funding.
Forward outlook
revenue growth
10–11 pct
FY 2028
management framework
Recommendation history
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
Earnings transcripts
Documents
FormReporting forFiledFlags